Skip to main content

Cardiovascular outcomes


08-14-2019 | Gestational diabetes | News

Metformin exposure during pregnancy may impact postnatal growth trajectory

Infants born to mothers with gestational diabetes treated with metformin have lower birthweight, but experience accelerated postnatal growth and have higher BMI in childhood, compared with those whose mothers were treated with insulin, suggest findings from a meta-analysis.

08-06-2019 | Metformin | Highlight | News

Support for metformin cardioprotective effect

Findings from the SAVOR-TIMI 53 trial suggest that metformin treatment reduces cardiovascular and all-cause mortality but not nonfatal cardiovascular disease events, but a meta-analysis points to wider benefits.

08-05-2019 | Dyslipidemia | News

Very low LDL could be protective in diabetic dyslipidemia

Achieving very low levels of low-density lipoprotein cholesterol while on statin treatment may reduce the risk for cardiovascular disease in people with type 2 diabetes and metabolic dyslipidemia, suggest the results of a large observational study.

06-25-2019 | Hypertension | ADA 2019 | News

Stricter BP thresholds may be needed in type 1 diabetes

Findings from an observational cohort study suggest that a blood pressure target of 120/80 mmHg may be needed for effective prevention of coronary artery disease in people with type 1 diabetes.

06-13-2019 | Dapagliflozin | ADA 2019 | News

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

06-12-2019 | Canagliflozin | ADA 2019 | News

Canagliflozin benefits span multiple cardiovascular backgrounds

Canagliflozin reduces the risk for major cardiovascular events and kidney failure versus placebo in patients with type 2 diabetes and chronic kidney disease with and without a known history of cardiovascular disease, CREDENCE study data show.

06-12-2019 | DPP-4 inhibitors | ADA 2019 | News

CARMELINA findings confirmed in highest CV risk subgroups

Secondary data from the CARMELINA trial, presented at the 79th ADA Scientific Sessions in San Francisco, California, USA, confirm the positive primary cardiovascular and renal safety findings, this time in particularly high-risk patients.

06-11-2019 | Semaglutide | ADA 2019 | News

Oral semaglutide falls just short of cardioprotection in event-driven PIONEER 6

The PIONEER 6 trial demonstrates the noninferior cardiovascular safety profile of oral semaglutide compared with placebo, but fails to demonstrate superiority, despite an overall positive trend and significance for cardiovascular death.

06-11-2019 | Linagliptin | ADA 2019 | News

CAROLINA shows neutral cardiovascular profile for modern sulfonylurea

The dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride have similar cardiovascular safety profiles, show the results of the CAROLINA trial.

06-10-2019 | Dulaglutide | ADA 2019 | News

Dulaglutide cardioprotective in relatively low-risk REWIND population

The glucagon-like peptide-1 receptor agonist dulaglutide has demonstrated significant cardioprotection in the REWIND trial, despite the trial population being lower risk than usual for cardiovascular outcome trials.

06-09-2019 | SGLT2 inhibitors | ADA 2019 | News

SGLT2 inhibitor, GLP-1 receptor agonist risk–benefits explored in older adults

Older people starting treatment with sodium-glucose cotransporter 2 inhibitors have a lower risk for hospitalization for heart failure than those starting glucagon-like peptide-1 receptor agonists, research shows.

06-09-2019 | Type 2 diabetes | ADA 2019 | News

Short-term delays in diabetes onset confer long-term cardioprotective effects

Delaying diabetes onset by at least 6 years in people with impaired glucose tolerance significantly reduces their risk for cardiovascular disease and microvascular complications, show 30-year data from the Da Qing Diabetes Prevention Study.

04-29-2019 | Hypertension | News

ADVANCE analysis fuels debate on BP targets in type 2 diabetes

A post-hoc analysis of the ADVANCE trial indicates that people with type 2 diabetes may benefit from additional antihypertensive medications even if their blood pressure is already below the 140/90 mmHg target.

04-26-2019 | Diabetes prevention | News

Da Qing study: Lifestyle intervention benefits persist for decades

Lifestyle interventions to delay the onset of type 2 diabetes result in marked long-term reductions in cardiovascular disease and mortality, shows the 30-year follow-up of the Da Qing Diabetes Prevention Outcome Study.

04-11-2019 | Empagliflozin | News

EMPRISE shows real-world HF protection with empagliflozin

An interim analysis of EMPRISE shows reductions in heart failure risk with empagliflozin in real-world users that match those reported in the EMPA-REG OUTCOME trial.

04-10-2019 | Cardiovascular outcomes | News

Existing CV disease confers high short-term vascular risk in type 2 diabetes

People with type 2 diabetes are more likely to experience cardiovascular events, particularly myocardial infarction, within 3 years of starting glucose-lowering therapy if they have pre-existing ischemic heart disease, research shows.

04-09-2019 | Cardiovascular outcomes | News

Registry study confirms high CVD, mortality risk of early-onset type 2 diabetes

Research using the Swedish National Diabetes Registry shows that diabetes confers a particularly high relative risk for mortality and multiple cardiovascular disease outcomes in people who are young when diagnosed.

03-18-2019 | Dapagliflozin | Highlight | News

DECLARE analyses show dapagliflozin benefits for reduced ejection fraction, prior MI subgroups

Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.

03-17-2019 | Canagliflozin | News

Canagliflozin may reduce HF events irrespective of ejection fraction

A post-hoc analysis of the CANVAS trial suggests that treatment with the sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk for heart failure events regardless of whether patients have preserved or reduced ejection fraction.

03-12-2019 | Hypoglycemia | DUKPC 2019 | News

Nurse-led intervention can reduce mortality risk after severe hypoglycemia

Assigning people with type 2 diabetes to 3 months of focused care with a specialist diabetes nurse after an episode of severe hypoglycemia reduces their risk for mortality over the following few years, research shows.

03-04-2019 | SGLT2 inhibitors | News

Meta-analysis confirms SGLT2 inhibitor heart failure, kidney disease benefits

Sodium-glucose cotransporter-2 inhibitors have a greater effect than glucagon-like peptide-1 receptor agonists on reducing hospitalization for heart failure and kidney disease progression in patients with type 2 diabetes, according to the findings of a systematic review and meta-analysis.

02-13-2019 | Cardiovascular outcomes | News

Increased glycemic variability predicts MACE in diabetes patients with ACS

A high degree of glycemic variability is associated with a significantly increased risk for midterm major cardiovascular events in patients with diabetes and acute coronary syndrome, French researchers report.

01-29-2019 | Cardiovascular outcomes | Highlight | News

Gap in cardiovascular risk not closing for people with type 2 diabetes

The incidence of coronary heart disease has declined in recent years but people with type 2 diabetes continue to have a significantly greater risk than those without, Scottish data show.

01-28-2019 | Glycemic control | News

Longitudinal glycemic variation linked to increased mortality risk

Long-term variation in fasting blood glucose may be associated with an increased risk for all-cause mortality, but not cardiovascular disease events, in people with no history of diabetes, US researchers report.

01-16-2019 | Diabetes prevention | News

Observational data highlight importance of diabetes prevention in midlife

Individuals who maintain a blood glucose level below the diabetes threshold during middle age have a lower risk for cardiovascular disease than those who convert to diabetes during this time, observational study data show.

01-14-2019 | Mental health | News

High mental illness burden in young-onset type 2 diabetes

Over a third of time spent in hospital before the age of 40 years by patients who develop type 2 diabetes by this age is due to mental illness, report researchers.

01-08-2019 | Dapagliflozin | News

Observational data hint at additional dapagliflozin benefits

A real-world study based on DECLARE-TIMI 58 inclusion and outcome criteria shows that dapagliflozin not only reduces cardiovascular risk among patients with type 2 diabetes, in line with the original trial results, but may also lower all-cause mortality risk.

01-03-2019 | Cardiovascular outcomes | News

Coronary artery calcification predicts coronary events in type 1 diabetes

The risk for coronary artery disease increases significantly with increasing levels of coronary artery calcification in individuals with type 1 diabetes, US researchers report.

12-07-2018 | Liraglutide (T2DM) | News

Liraglutide cardioprotection replicated in real-world data

Registry data from Denmark and Sweden uphold the cardioprotective effects of liraglutide observed in randomized trials, with the strongest effects seen in patients with established cardiovascular disease.

12-03-2018 | Liraglutide (T2DM) | medwireNews | News

Older type 2 diabetes patients may derive greatest liraglutide benefits

The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.

12-03-2018 | Epidemiology | News

Global burden of vascular complications ‘substantial’ in early type 2 diabetes

Patients initiating second-line therapy for type 2 diabetes have a substantial burden of both microvascular and macrovascular complications, which varies by global region, the DISCOVER study investigators report.

11-12-2018 | SGLT2 inhibitors | News

Meta-analysis supports cardioprotective benefits of SGLT2 inhibitors

Sodium-glucose cotransporter 2 inhibitors reduce the risk for heart failure hospitalization and renal disease progression in patients with type 2 diabetes regardless of existing cardiovascular disease, meta-analysis data show.

11-10-2018 | Dapagliflozin | Highlight | News

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

11-06-2018 | Cardiovascular outcomes | Highlight | News

Type 2 diabetes, polyvascular disease combine to increase cardiovascular risk

Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.

10-18-2018 | Empagliflozin | News

Up to 4.5 years’ life gained with SGLT2 inhibition in EMPA REG

The protective effect of empagliflozin against cardiovascular and all-cause mortality translates into between 1.0 and 4.5 years of additional life expectancy for high-risk patients with type 2 diabetes, say the EMPA REG OUTCOME investigators.

10-17-2018 | Liraglutide (T2DM) | News

Cardiovascular benefits of liraglutide in type 2 diabetes apply to high-risk subgroups

The cardioprotective effects of liraglutide apply to patients with chronic kidney disease as well as those with established cardiovascular disease, show two post-hoc analyses of the LEADER trial.

10-16-2018 | Metabolic surgery | medwireNews | News

Marked reduction in vascular events in diabetes patients after bariatric surgery

An observational study published in JAMA demonstrates a substantial reduction in the risk for hard cardiovascular endpoints in obese patients with type 2 diabetes who have undergone bariatric surgery.

10-05-2018 | Linagliptin | EASD 2018 | News

Favorable long-term cardiovascular safety profile of linagliptin in type 2 diabetes

Findings from the CARMELINA trial suggest that the dipeptidyl peptidase-4 inhibitor linagliptin has a similar cardiovascular safety profile to placebo when added to standard care in high-risk type 2 diabetes patients.

10-02-2018 | Albiglutide | EASD 2018 | News

Albiglutide reduces cardiovascular risk in patients with type 2 diabetes

Results of the Harmony Outcomes trial indicate that adding the glucagon-like peptide-1 receptor agonist albiglutide to standard care may reduce cardiovascular risk among patients with type 2 diabetes and existing cardiovascular disease.

09-25-2018 | Hypertension | News

Reweighting simulation may reconcile SPRINT, ACCORD BP findings

Research suggests that giving patients with type 2 diabetes intensive blood pressure treatment as per the ACCORD BP study would be beneficial in a real-world US population.

09-05-2018 | Heart failure | News

Network meta-analysis backs SGLT2 inhibitors for heart failure prevention

The results of a network meta-analysis offer strong support for use of sodium-glucose cotransporter 2 inhibitors to prevent heart failure (HF) in patients with type 2 diabetes.

08-26-2018 | Cardiovascular outcomes | Highlight | News

ASCEND results question the use of aspirin, omega-3 supplements in diabetes patients

Findings from a phase IV trial suggest that aspirin use may reduce the risk for primary vascular events but at the cost of increased major bleeding risk in patients with diabetes, while omega-3 fatty acid supplementation does not have a cardioprotective effect.

08-26-2018 | Lorcaserin | Highlight | News

Neutral cardiovascular safety for lorcaserin in CAMELLIA-TIMI 61

The weight-loss medication lorcaserin neither increases nor reduces cardiovascular risk, report the CAMELLIA–TIMI 61 investigators.

08-16-2018 | Risk factors | Highlight | News

Risk factor control may mitigate excess cardiovascular, mortality risk in type 2 diabetes

A study of the Swedish National Diabetes Register suggests that keeping five cardiovascular risk factor variables within the target ranges could offset the excess risk for death, myocardial infarction, or stroke among patients with type 2 diabetes relative to the general population.

08-10-2018 | Cardiovascular outcomes | Highlight | News

Earlier onset of type 1 diabetes associated with increased risk for adverse outcomes

Patients with type 1 diabetes diagnosed before the age of 10 years have a higher risk for cardiovascular complications and a shorter life expectancy than those who develop the disease at an older age, study results published in The Lancet suggest.

08-08-2018 | Medication adherence | News

Early diabetes medication nonadherence has grave outcomes

Patients who are not diligent about taking their antidiabetic medications during the first year after type 2 diabetes diagnosis are at increased risk for cardiovascular events and death over the subsequent years, research shows.

08-07-2018 | Cardiovascular outcomes | News

Prevalent CVD impacts cardiovascular risk prediction in type 2 diabetes

The best markers for prediction of cardiovascular events in patients with type 2 diabetes may vary according to whether or not the patient already has cardiovascular disease, study findings indicate.

07-25-2018 | Cardiovascular outcomes | News

Diabetes and extreme temperatures combine to increase MI risk

Having diabetes exacerbates the adverse effects of extreme temperatures on people’s risk for having an acute myocardial infarction, say researchers.

07-18-2018 | Sulfonylureas | Highlight | News

Continuing metformin advisable for patients starting sulfonylurea treatment

Research shows that starting second-line sulfonylurea treatment is associated with an increased risk for cardiovascular and hypoglycemic events among patients with type 2 diabetes in clinical practice, although the risk is less if they continue using metformin rather than switching completely.

07-18-2018 | Cardiovascular outcomes | News

CVD risk scores may be inappropriate in newly diagnosed type 2 diabetes

An evaluation of several cardiovascular disease risk scores has highlighted poor performance of these tools among individuals with newly diagnosed type 2 diabetes.

07-10-2018 | Canagliflozin | News

CANVAS analysis supports canagliflozin CV benefit at low renal function

A secondary analysis of the CANVAS trial supports the beneficial cardiovascular and renal effects of sodium-glucose cotransporter 2 inhibition down to a low level of kidney function.

07-04-2018 | Heart failure | News

Heart failure particularly high risk in type 1 diabetes patients

The likelihood of dying during or soon after heart failure hospitalization is higher among patients with type 1 than type 2 diabetes, report researchers.

06-25-2018 | Cardiovascular outcomes | ADA 2018 | News

High risk with earlier diabetes onset seen in older population

Analysis of the Health and Retirement Study indicates that the adverse effects of earlier age of type 2 diabetes onset are also evident in an older population.

06-24-2018 | Lifestyle interventions | ADA 2018 | News

Lifestyle intervention cuts long-term CVD events in people at risk for diabetes

A 6-year diet and exercise intervention significantly reduces the long-term risk for cardiovascular disease in Chinese adults with impaired glucose tolerance, research suggests.

06-20-2018 | Cardiovascular outcomes | News

Healthy lifestyle halves CVD risk in type 2 diabetes

Following a healthy lifestyle halves the risk for developing cardiovascular disease in adults with type 2 diabetes, research shows.

06-08-2018 | Heart failure | News

Established biomarker predicts HF in type 2 diabetes

When levels of N-terminal pro B-type natriuretic peptide are persistently high or rising, patients with type 2 diabetes are at increased risk for being hospitalized with heart failure or dying of cardiovascular causes, research shows.

06-06-2018 | Cardiovascular outcomes | News

Men with cardiometabolic disease bear brunt of work stress risk

Research from the IPD-Work consortium indicates that the mortality risk associated with work stress is largely confined to men with cardiometabolic disease.

05-31-2018 | Obesity | Highlight | News

Yet more evidence against metabolically healthy obesity

Another two large studies have demonstrated that people who appear to be in good health despite being obese do not remain so for long.

05-21-2018 | Epidemiology | News

US mortality trends shifting in patients with diabetes

Mortality rates in people with diabetes are falling faster than in those without diabetes, with the greatest decline seen in deaths from vascular causes, US study data show.

05-14-2018 | Nephropathy | News

Real-world data support intensive risk factor control in diabetes patients with CKD

Data from primary care indicate that more successful control of vascular risk factors in patients with type 2 diabetes and chronic kidney disease is associated with reduced risk for cardiovascular disease and mortality.

05-10-2018 | Specific populations | Highlight | News

Women bear brunt of diabetes effect on atherosclerosis mortality

An individual patient data meta-analysis confirms that diabetes increases the likelihood for people dying of atherosclerotic disease, with women the worst affected.

04-17-2018 | Medications | News

Modern antidiabetic medications ranked for survival benefits

A network meta-analysis published in JAMA offers indirect comparisons of the survival benefits associated with use of the most recent antidiabetic agents.

04-03-2018 | Alogliptin | Highlight | News

Support for alogliptin as add-on therapy for type 2 diabetes

Adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin and sulfonylurea treatment may improve glycemic control in patients with type 2 diabetes and high cardiovascular risk, a post-hoc analysis of the EXAMINE trial suggests.

03-29-2018 | Risk factors | News

Population-based risk factor management reduces CV risk in diabetes patients

A drive to improve cardiovascular risk factors at the level of the healthcare system results in reduced vascular risk in patients with diabetes, research shows.

03-26-2018 | Complications | News

Diabetes duration, control impact cause-specific mortality in Mexico

Deaths from vascular, renal, and infectious causes substantially increase with increasing diabetes duration and worsening glycemic control, results of the Mexico City Prospective Study show.

03-19-2018 | Obesity | News

Further evidence challenges obesity paradox

UK Biobank data add to the evidence challenging the existence of the obesity paradox by showing that cardiovascular disease risk increases linearly with increasing adiposity in middle-aged men and women.

03-15-2018 | Type 2 diabetes | News

Early diabetes onset linked to increased mortality risk

Study results presented at the 2018 Diabetes UK Professional Conference in London confirm that people who are diagnosed with type 2 diabetes at a younger age have an increased mortality risk.

03-11-2018 | SGLT2 inhibitors | News

CVD-REAL 2 extends SGLT2 inhibitor benefits beyond US and European populations

The latest analysis from the CVD-REAL 2 investigators shows reduced cardiovascular risk associated with sodium-glucose cotransporter 2 inhibitor use among diabetes patients from Asia Pacific, North America, and the Middle East.

02-08-2018 | Cardiovascular outcomes | News

Further support for cardiovascular benefits of canagliflozin

Results of a US database study suggest that the sodium-glucose co-transporter-2 inhibitor canagliflozin is associated with a lower risk for heart failure hospitalization compared with three other classes of antidiabetes agent.

02-05-2018 | Cardiovascular outcomes | News

Low BP may flag cardiac risk in diabetes patients

Analysis of the SAVOR-TIMI trial supports a relationship between low blood pressure and cardiovascular risk in patients with type 2 diabetes.

01-22-2018 | Hypoglycemia | News

Bidirectional relationship evident between severe hypoglycemia and CV events

An analysis of TECOS data highlights a bidirectional relationship between severe hypoglycemic events and adverse cardiovascular outcomes in patients with type 2 diabetes.

12-14-2017 | Empagliflozin | News

Plasma volume reduction may explain much of empagliflozin cardioprotective effect

A mediation analysis indicates that empagliflozin may provide cardioprotection largely through its ability to reduce plasma volume, with traditional cardiovascular risk markers playing little or no role.

12-13-2017 | Cardiovascular outcomes | News

Prognostic value of UACR depends on availability of cardiac biomarkers

An increased urinary albumin to creatinine ratio is significantly and independently associated with an increased risk for cardiovascular outcomes in patients with type 2 diabetes, an analysis of SAVOR-TIMI 53 data shows.

12-12-2017 | Anti-hypertensive medications | News

Intensive BP treatment back on table for diabetes patients

Intensive blood pressure management benefits patients whether or not they have diabetes and regardless of their baseline level of cardiovascular disease risk, shows a pooled analysis of the SPRINT and ACCORD-BP trials.

12-08-2017 | Cardiovascular outcomes | News

Meta-analysis may support cardioprotective class effect for GLP-1 receptor agonists

A meta-analysis published in The Lancet Diabetes & Endocrinology is suggestive of a class cardioprotective effect for the glucagon-like peptide-1 receptor agonists.

12-01-2017 | Obesity | News

Surrogate BMI approach supports overweight mortality risk

A novel approach of using children’s BMI as a surrogate for their parents’ weight confirms that overweight and obesity increase people’s mortality risk.

11-23-2017 | Cardiovascular outcomes | News

Intensive diabetes treatment reduces CVD risk even with excessive weight gain

Intensive treatment of type 1 diabetes appears to reduce the risk for cardiovascular disease events even in those who gain excessive weight, but improved management of cardiovascular risk factors and revascularization may be needed.

11-14-2017 | Canagliflozin | News

Canagliflozin benefits may extend to primary prevention

Further analysis of the CANVAS trial suggests that the benefits of canagliflozin treatment are broadly consistent in type 2 diabetes patients with and without pre-existing cardiovascular disease,

11-13-2017 | Older adults | News

CV complications impact survival in elderly type 2 diabetes patients

Cardiovascular complications, and heart failure in particular, are strongly associated with poor survival in elderly patients with type 2 diabetes, French observational study data show.

11-09-2017 | Cardiovascular outcomes | News

Diabetes links sleep habits to CHD risk

Researchers say that incident diabetes may explain why sleep patterns affect coronary heart disease risk.

11-01-2017 | Adolescents | News

No renal benefits of ACE inhibitor, statin treatment in adolescents with type 1 diabetes

Results of AdDIT show that treatment with an ACE inhibitor, a statin, or both does not protect against the increased albumin excretion that frequently occurs in patients with type 1 diabetes during adolescence.

10-25-2017 | DPP-4 inhibitors | News

Metformin may moderate DDP-4 inhibitor effect on cardiovascular outcomes

Metformin status at the time of initial dipeptidyl peptidase 4 inhibitor use may influence the effect these agents have on cardiovascular outcomes, be it positive or negative, suggest results of a hypothesis-generating meta-analysis.

10-19-2017 | Vildagliptin | News

Unclear impact of vildagliptin treatment in patients with HF and type 2 diabetes

Results of the VIVIDD trial indicate that it is unclear whether treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin has a beneficial effect on cardiac outcomes among patients with heart failure and type 2 diabetes.

10-18-2017 | Heart failure | News

Glycemic control, drug treatment linked to outcome in patients with HF and type 2 diabetes

Results of a study published in JACC: Heart Failure suggest that glycemic control and drug treatment have complex associations with adverse outcomes among patients with heart failure and type 2 diabetes.

10-16-2017 | Gestational diabetes | News

Healthy lifestyle may mitigate CVD risk following gestational diabetes

Women with a history of gestational diabetes have a significantly increased risk for cardiovascular disease, which may be modified by healthy lifestyle factors, prospective study data show.

10-12-2017 | Cardiovascular outcomes | News

Low grip strength flags high CVD risk in diabetes patients

Low grip strength may identify people with diabetes who are at particularly high risk for cardiovascular disease, UK research suggests.

10-11-2017 | Heart failure | News

Sudden death tops CV death causes in type 2 diabetics with atherosclerosis

Sudden death is the most common cause of cardiovascular death among patients with type 2 diabetes and atherosclerotic cardiovascular disease, an analysis of TECOS data shows.

10-02-2017 | Cardiovascular outcomes | News

Intensive BP control may be beneficial for high-risk type 2 diabetes patients

A post-hoc analysis of the ACCORD-BP trial suggests that the presence of additional cardiovascular risk factors may be key for patients with type 2 diabetes to derive benefit from intensive blood pressure control.

09-27-2017 | Cardiovascular outcomes | News

Echocardiographic profiling could guide cardiovascular risk reduction in type 2 diabetes patients

Patients with type 2 diabetes can be divided into three groups with distinct clinical profiles based on echocardiographic measures, researchers report.

09-22-2017 | Physical activity | News

PURE study shows global physical activity benefits

The PURE study shows that the cardiovascular disease and mortality risk reductions attainable with regular physical activity apply regardless of whether people live in countries with high, middle, or low income.

09-21-2017 | Type 2 diabetes | EASD 2017 | News

Novel compounds show promise for type 2 diabetes

Study results presented at the EASD annual meeting in Lisbon, Portugal, demonstrated the potential of several novel therapies for the treatment of obesity-related metabolic dysfunction and type 2 diabetes.

09-20-2017 | Hypoglycemia | EASD 2017 | News

Hypoglycemia: Risk factors and Ramadan

Results presented during an EASD annual meeting session on hypoglycemia covered risk factors and consequences, and looked at the optimal insulin management approach for diabetes patients wishing to observe Ramadan.

09-20-2017 | Non-alcoholic fatty liver disease | EASD 2017 | News

NAFLD: The associated risks and potential treatments

Researchers presented the results of several studies investigating the risks associated with nonalcoholic fatty liver disease and potential treatment strategies at the EASD annual meeting in Lisbon, Portugal.

09-19-2017 | Cardiovascular outcomes | EASD 2017 | News

Simple wellbeing query predicts MACE in type 2 diabetes

Asking two simple questions about the vitality and energy of patients with type 2 diabetes may help healthcare providers to predict their risk for major adverse cardiovascular events.

09-19-2017 | Empagliflozin | EASD 2017 | News

Benefits of empagliflozin unlikely to be mediated by control of cardiovascular risk factors

Analysis of data from the EMPA-REG OUTCOME trial suggests that the beneficial effects of empagliflozin on mortality risk in patients with type 2 diabetes and established cardiovascular disease occur independently of its influence on traditional cardiovascular risk factors.

09-18-2017 | PCSK9 inhibitors | EASD 2017 | News

FOURIER: Evolocumab cardiovascular benefits extend to diabetes patients

A prespecified analysis of the FOURIER trial shows that the PCSK9 inhibitor evolocumab is as beneficial in patients with diabetes as in those without.

09-15-2017 | Exenatide | EASD 2017 | News

EXSCEL: Near miss for exenatide cardioprotection

The results of the Exenatide Study of Cardiovascular Event Lowering study show that the glucagon-like peptide-1 receptor agonist has a neutral cardiovascular effect, the investigators have reported at the EASD annual meeting, in Lisbon, Portugal.

09-14-2017 | SGLT2 inhibitors | EASD 2017 | News

Latest CVD-REAL data bolster cardioprotective effects of SGLT2 inhibition

The CVD-REAL investigators have presented further results demonstrating the effects of sodium-glucose co-transporter 2 inhibitors on cardiovascular outcomes in real-world clinical practice.

09-13-2017 | Pioglitazone | EASD 2017 | News

TOSCA.IT: Similar long-term CV safety profile for pioglitazone, sulfonylurea

 The TOCSA.IT investigators have found no differences in cardiovascular disease outcomes between patients with type 2 diabetes taking pioglitazone versus sulfonylurea over nearly 5 years.

09-13-2017 | Acarbose | EASD 2017 | News

ACE results suggest no reduction in CV risk with acarbose treatment

The α-glucosidase inhibitor acarbose does not reduce cardiovascular risk but could decrease the risk for developing type 2 diabetes among patients with coronary heart disease and impaired glucose tolerance, results of the phase IV placebo-controlled ACE trial suggest.

Image Credits